POLIO VACCINES MARKET ANALYSIS

Polio Vaccines MarketSize and Trends

According to UNICEF report, Bio Farma (Indonesia), GlaxoSmithKline (GSK) (UK) and Sanofi Pasteur (France) are the only OPV bulk manufacturers. Novartis (Switzerland) has stopped their manufacture of OPV.

Market scenario varies with change in continents and is expected to affect the polio vaccines market:

There are only 3 countries left in which wild polio infections still persist; Afghanistan, Nigeria, and Pakistan, which are somehow the reason for significant growth in the polio vaccines market in the near future.

Indigenous wild poliovirus type 2 has not been detected since 1999. In 2015, the World Health Assembly agreed that all Member States which currently use OPV should prepare for the global withdrawal of the type 2 component of OPV in April 2016. According to WHO, member countries are required to introduce at least 1 dose of the IPV into routine immunization schedule.

Sanofi Pasteur and Bilthoven Biologicals/ Serum Institute of India are the 2 companies which was awarded in 2014 by UNICEF for the supply of IPV in 1, 5 and 10 dose vials, and long term supply agreements were established through to 2018.

Since 2000, UNICEF OPV procurement has averaged 1.8 Bn doses annually. GPEI launched the “End Game Strategic Plan 2013-2018” at the World Health Assembly in May 2013. This comprehensive strategy focuses on eliminating both wild and vaccine-derived polio incidence through routine immunization programs thereby gradually replacing OPV use with IPV vaccine. This in turn is expected to favour the growth in polio vaccines industry in the near future.